Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Gimeno, Ramón
- dc.contributor.author Ribas-Llauradó, Clara
- dc.contributor.author Pesqué, David
- dc.contributor.author Andrades, Evelyn
- dc.contributor.author Cenni, Bruno
- dc.contributor.author Ambros, Barbara
- dc.contributor.author Pujol Vallverdú, Ramon Maria
- dc.contributor.author Giménez Arnau, Anna Maria
- dc.date.accessioned 2023-05-23T06:04:45Z
- dc.date.available 2023-05-23T06:04:45Z
- dc.date.issued 2023
- dc.description.abstract Despite advances in the treatment of chronic urticaria, in a significant percentage of the patients symptoms are not fully controlled with conventional approaches. New strategies under development include blocking intracellular mediators of mast cell and basophil activation. We aim to investigate the effects of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib on human blood basophils and CD34+-derived mast cells activation induced by serum obtained from chronic urticaria patients. Twenty-two patients with chronic spontaneous urticaria (mean age 52 years, 27% women) and 22 patients with chronic inducible urticaria (46 years, 27% women) were included in the study together with a sex-matched control group. Patients were classified as responders or non-responders to anti-IgE therapy on the basis of their clinical data, FcεR1a expression on blood basophils and total IgE levels. Changes on CD63 expression—as an activation marker-, were used to evaluate in vitro the response of basophils and mast cells to serum exposure and the inhibitory effects of remibrutinib. Remibrutinib inhibits degranulation induced by IgE cross-linking in mast cells and basophils and also the activation triggered by factors present in the sera of spontaneous and inducible chronic urticaria patients. Patient's serum induces a greater degranulation of effector cells than controls. Activation of mast cells and basophils by patient sera and remibrutinib effects were not related to omalizumab responsiveness. Remibrutinib inhibits activation of human basophils and mast cells induced in vitro by exposure to the serum of chronic urticaria patients independently of their response to omalizumab.
- dc.format.mimetype application/pdf
- dc.identifier.citation Gimeno R, Ribas‐Llauradó C, Pesque D, Andrades E, Cenni B, Ambros B, et al. Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response. Clinical & Translational All. 2023 Mar;13(3):e12227. DOI: 10.1002/clt2.12227
- dc.identifier.doi http://dx.doi.org/10.1002/clt2.12227
- dc.identifier.issn 2045-7022
- dc.identifier.uri http://hdl.handle.net/10230/56927
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Clinical and Translational Allergy. 2023 Mar;13(3):e12227
- dc.rights © 2023 The Authors. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Basophils
- dc.subject.keyword Bruton's tyrosine kinase
- dc.subject.keyword Chronic urticaria
- dc.subject.keyword IgE
- dc.subject.keyword Mast cells
- dc.subject.keyword Omalizumab
- dc.subject.keyword Remibrutinib
- dc.title Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion